Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic

Table 3 Univariate analyses of survival outcomes by patient and treatment-related factors

	Overall Survival, HR (95 % CI)	Time to loco-regional recurrence, mos (95 % CI)	Time to distant metastases, mos (95 % CI)
LRR vs. NP SCCHN	0.84 (0.49–1.49)	1.05 (0.51–2.38)	0.99 (0.58–1.77)
LRR vs. NP SCCHN	P = 0.53	P = 0.91	P = 0.96
Age at diagnosis of LRR/NP SCCHN	1.4 (0.84–2.36)	1.01 (0.52–2.03)	1.62 (0.97–2.77)
< 60 vs. ≥ 60	P = 0.2	P = 0.97	P = 0.07
Sex	0.92 (0.52–1.71)	0.53 (0.27–1.15)	0.98 (0.54–1.91)
Male vs. Female	P = 0.78	P = 0.1	P = 0.95
Tobacco abuse	0.67 (0.86–2.72)	1.84 (0.26–1.12)	0.82 (0.71–2.16)
< 20 PY vs. > 20 PY	P = 0.16	P = 0.1	P = 0.48
Post-operative vs. Definitive RRT	0.67 (0.4–1.11)	0.62 (0.31–1.23)	0.67 (0.4–1.1)
Post-operative vs. Definitive RRT	P = 0.12	P = 0.17	P = 0.12
Time since primary SCCHN	0.77 (0.44–1.3)	1.19 (0.43–1.73)	0.79 (0.75–2.18)
< 24 mos vs. ≥ 24 mos	P = 0.33	P = 0.63	P = 0.39
Chemotherapy vs. no chemotherapy with RRT	1.47 (0.82–2.84)	2.43 (1.02–7.16)	1.12 (0.66–1.98)
Chemotherapy vs. no chemotherapy with RRT	P = 0.2	P = 0.04	P = 0.68
Platinum vs. cetuximab with RRT	0.65 (0.36–1.22)	0.4 (0.19–0.86)	0.65 (0.33–1.31)
Platinum vs. cetuximab with RRT	P = 0.18	P = 0.02	P = 0.22
IMRT versus other	0.99 (0.4–3.32)	2.03 (0.43–36.2)	1.21 (0.49–4.04)
IMRT versus other	P = 0.99	P = 0.44	P = 0.71

CI confidence interval, HR hazard ratio, IMRT intensity modulated radiation therapy, LRR loco-regionally recurrent, NP new primary, NR not reached, PY pack-years, RRT reirradiation therapy, SCCHN squamous cell carcinoma of head and neck

ISSN: 1748-717X